Cargando…
Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients
In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples i...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890139/ https://www.ncbi.nlm.nih.gov/pubmed/29662479 http://dx.doi.org/10.3389/fmicb.2018.00555 |
_version_ | 1783312811311497216 |
---|---|
author | Postina, Patricia Skladny, Julian Boch, Tobias Cornely, Oliver A. Hamprecht, Axel Rath, Peter-Michael Steinmann, Jörg Bader, Oliver Miethke, Thomas Dietz, Anne Merker, Natalia Hofmann, Wolf-Karsten Buchheidt, Dieter Spiess, Birgit |
author_facet | Postina, Patricia Skladny, Julian Boch, Tobias Cornely, Oliver A. Hamprecht, Axel Rath, Peter-Michael Steinmann, Jörg Bader, Oliver Miethke, Thomas Dietz, Anne Merker, Natalia Hofmann, Wolf-Karsten Buchheidt, Dieter Spiess, Birgit |
author_sort | Postina, Patricia |
collection | PubMed |
description | In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples is crucial. In addition to the in-house azole resistance ARAf polymerase chain reaction (PCR) assays detecting the frequent mutation combinations TR34/L98H, TR46/Y121F/T289A, and M220 in the Aspergillus fumigatus (A. fumigatus) Cyp51A gene by subsequent DNA sequence analysis, we investigated in parallel the commercially available AsperGenius® real time PCR system in detecting the Cyp51A alterations TR34/L98H and Y121F/T289A directly from 52 clinical samples (15 biopsies, 22 bronchoalveolar lavage (BAL), 15 cerebrospinal fluid (CSF) samples) and ARAf isolates (n = 3) of immunocompromised patients. We analyzed DNA aliquots and compared both methods concerning amplification and detection of Aspergillus DNA and Cyp51A alterations. As positive control for the feasibility of our novel Y121F and T289A PCR assays, we used two A. fumigatus isolates with the TR46/Y121F/T289A mutation combination isolated from hematological patients with known Cyp51A alterations and a lung biopsy sample of a patient with acute myeloid leukemia (AML). The rate of positive ARAf PCR results plus successful sequencing using the ARAf PCR assays was 61% in biopsies, 29% in CSF, 67% in BAL samples and 100% in isolates. In comparison the amount of positive PCRs using the AsperGenius® assays was 47% in biopsies, 42% in CSF, 59% in BAL samples and 100% in isolates. Altogether 17 Cyp51A alterations were detected using our ARAf PCRs plus DNA sequencing and therefrom 10 alterations also by the AsperGenius® system. The comparative evaluation of our data revealed that our conventional PCR assays are more sensitive in detecting ARAf in BAL and biopsy samples, whereby differences were not significant. The advantage of the AsperGenius® system is the time saving aspect. We consider non-culture based molecular detection of Aspergillus triazole resistance to be of high epidemiological and clinical relevance in patients with hematological malignancies. |
format | Online Article Text |
id | pubmed-5890139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58901392018-04-16 Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients Postina, Patricia Skladny, Julian Boch, Tobias Cornely, Oliver A. Hamprecht, Axel Rath, Peter-Michael Steinmann, Jörg Bader, Oliver Miethke, Thomas Dietz, Anne Merker, Natalia Hofmann, Wolf-Karsten Buchheidt, Dieter Spiess, Birgit Front Microbiol Microbiology In hematological patients, the incidence of invasive aspergillosis (IA) caused by azole resistant Aspergillus fumigatus (ARAf) is rising. As the diagnosis of IA is rarely based on positive culture in this group of patients, molecular detection of resistance mutations directly from clinical samples is crucial. In addition to the in-house azole resistance ARAf polymerase chain reaction (PCR) assays detecting the frequent mutation combinations TR34/L98H, TR46/Y121F/T289A, and M220 in the Aspergillus fumigatus (A. fumigatus) Cyp51A gene by subsequent DNA sequence analysis, we investigated in parallel the commercially available AsperGenius® real time PCR system in detecting the Cyp51A alterations TR34/L98H and Y121F/T289A directly from 52 clinical samples (15 biopsies, 22 bronchoalveolar lavage (BAL), 15 cerebrospinal fluid (CSF) samples) and ARAf isolates (n = 3) of immunocompromised patients. We analyzed DNA aliquots and compared both methods concerning amplification and detection of Aspergillus DNA and Cyp51A alterations. As positive control for the feasibility of our novel Y121F and T289A PCR assays, we used two A. fumigatus isolates with the TR46/Y121F/T289A mutation combination isolated from hematological patients with known Cyp51A alterations and a lung biopsy sample of a patient with acute myeloid leukemia (AML). The rate of positive ARAf PCR results plus successful sequencing using the ARAf PCR assays was 61% in biopsies, 29% in CSF, 67% in BAL samples and 100% in isolates. In comparison the amount of positive PCRs using the AsperGenius® assays was 47% in biopsies, 42% in CSF, 59% in BAL samples and 100% in isolates. Altogether 17 Cyp51A alterations were detected using our ARAf PCRs plus DNA sequencing and therefrom 10 alterations also by the AsperGenius® system. The comparative evaluation of our data revealed that our conventional PCR assays are more sensitive in detecting ARAf in BAL and biopsy samples, whereby differences were not significant. The advantage of the AsperGenius® system is the time saving aspect. We consider non-culture based molecular detection of Aspergillus triazole resistance to be of high epidemiological and clinical relevance in patients with hematological malignancies. Frontiers Media S.A. 2018-03-27 /pmc/articles/PMC5890139/ /pubmed/29662479 http://dx.doi.org/10.3389/fmicb.2018.00555 Text en Copyright © 2018 Postina, Skladny, Boch, Cornely, Hamprecht, Rath, Steinmann, Bader, Miethke, Dietz, Merker, Hofmann, Buchheidt and Spiess. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Postina, Patricia Skladny, Julian Boch, Tobias Cornely, Oliver A. Hamprecht, Axel Rath, Peter-Michael Steinmann, Jörg Bader, Oliver Miethke, Thomas Dietz, Anne Merker, Natalia Hofmann, Wolf-Karsten Buchheidt, Dieter Spiess, Birgit Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients |
title | Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients |
title_full | Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients |
title_fullStr | Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients |
title_full_unstemmed | Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients |
title_short | Comparison of Two Molecular Assays for Detection and Characterization of Aspergillus fumigatus Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients |
title_sort | comparison of two molecular assays for detection and characterization of aspergillus fumigatus triazole resistance and cyp51a mutations in clinical isolates and primary clinical samples of immunocompromised patients |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890139/ https://www.ncbi.nlm.nih.gov/pubmed/29662479 http://dx.doi.org/10.3389/fmicb.2018.00555 |
work_keys_str_mv | AT postinapatricia comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT skladnyjulian comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT bochtobias comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT cornelyolivera comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT hamprechtaxel comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT rathpetermichael comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT steinmannjorg comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT baderoliver comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT miethkethomas comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT dietzanne comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT merkernatalia comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT hofmannwolfkarsten comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT buchheidtdieter comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients AT spiessbirgit comparisonoftwomolecularassaysfordetectionandcharacterizationofaspergillusfumigatustriazoleresistanceandcyp51amutationsinclinicalisolatesandprimaryclinicalsamplesofimmunocompromisedpatients |